Similar Natural Products in NPASS
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC318947 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 23527 |
0.1-0.2 | 6233 |
0.2-0.3 | 790 |
0.3-0.4 | 210 |
0.4-0.5 | 98 |
0.5-0.6 | 19 |
0.6-0.7 | 8 |
0.7-0.8 | 4 |
0.8-0.85 | 0 |
0.85-0.9 | 0 |
0.9-0.95 | 0 |
0.95-1 | 0 |
  Similar Clinical/Approved Drugs
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC318947 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 3533 |
0.1-0.2 | 4866 |
0.2-0.3 | 496 |
0.3-0.4 | 177 |
0.4-0.5 | 67 |
0.5-0.6 | 13 |
0.6-0.7 | 7 |
0.7-0.8 | 1 |
0.8-0.85 | 1 |
0.85-0.9 | 0 |
0.9-0.95 | 0 |
0.95-1 | 0 |
Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8095 |
Intermediate Similarity |
NPD7383 |
Phase 3 |
0.7391 |
Intermediate Similarity |
NPD8560 |
Clinical (unspecified phase) |
0.6897 |
Remote Similarity |
NPD9040 |
Clinical (unspecified phase) |
0.6897 |
Remote Similarity |
NPD9041 |
Approved |
0.6897 |
Remote Similarity |
NPD9039 |
Approved |
0.6667 |
Remote Similarity |
NPD8791 |
Clinical (unspecified phase) |
0.6429 |
Remote Similarity |
NPD9012 |
Phase 2 |
0.6429 |
Remote Similarity |
NPD9013 |
Clinical (unspecified phase) |
0.6154 |
Remote Similarity |
NPD8221 |
Clinical (unspecified phase) |
0.5862 |
Remote Similarity |
NPD9063 |
Approved |
0.5862 |
Remote Similarity |
NPD9064 |
Approved |
0.5667 |
Remote Similarity |
NPD9465 |
Approved |
0.5667 |
Remote Similarity |
NPD8544 |
Approved |
0.5625
|
Remote Similarity |
NPD1156 |
Clinical (unspecified phase) |